Nano-Encapsulation of Brown Algal Fucoxanthin Enhances Bioavailability and Modulates Adiposity in Zebrafish (Danio rerio): Implications for Human Metabolic Syndrome
DOI:
https://doi.org/10.63001/tbs.2026.v21.i01.S.I(1).pp1018-1034Keywords:
Fucoxanthin,, nano- encapsulation,, metabolic syndrome,, zebrafish, obesity,, bioavailability, lipid nanoparticles,, brown algae.Abstract
Background: Metabolic syndrome (MetS) represents a cluster of interconnected risk factors including obesity, hyperglycaemia,
and dyslipidaemia, with increasing global prevalence. Fucoxanthin, a marine carotenoid from brown algae, exhibits anti-
obesity and anti-diabetic properties but its therapeutic application is limited by poor oral bioavailability.
Objective: To develop and characterize lipid-based nano capsules containing fucoxanthin (FUCO-LNCs) and evaluate their
enhanced bioavailability and therapeutic efficacy in ameliorating metabolic syndrome parameters using a zebrafish model of
diet-induced obesity.
Downloads
Published
2026-03-30
How to Cite
Dr. Jay Prakash Singh, Kiranjeet Kaur, Vipul Singh, Shubham Goutam, Sushant Kumar Sharma, Jitendra Kumar, … Dr. Gita Chaurasia. (2026). Nano-Encapsulation of Brown Algal Fucoxanthin Enhances Bioavailability and Modulates Adiposity in Zebrafish (Danio rerio): Implications for Human Metabolic Syndrome. The Bioscan, 21(Special Issue-1), 1018–1034. https://doi.org/10.63001/tbs.2026.v21.i01.S.I(1).pp1018-1034
Issue
Section
Articles
